Methoxyestradiol, once considered an inacitve end-metabolite of estradiol, has recently
emerged as a very promising agent for cancer treatment. It is orally active in a wide range of …

Inhibition of angiogenesis is an important new modality for cancer treatment. 2-
methoxyestradiol (2ME2) is a novel antitumor and antiangiogenic agent, currently in clinical …

Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …

Methoxyestradiol (2ME2) is an endogenous metabolite of 17β-estradiol (E2) that arises from
the hydroxylation and subsequent methylation at the 2-position. In vitro 2ME2 inhibits a large …

Background Standard chemotherapy remains inadequate in metastatic pancreatic
adenocarcinoma. Combining an agonistic CD40 monoclonal antibody with chemotherapy …

As the field of cancer immunotherapy continues to advance at a fast pace, treatment
approaches and drug development are evolving rapidly to maximize patient benefit. New …

Methoxyestradiol (2ME2), a natural metabolite of estradiol, is a potent antitumor and
antiangiogenic agent. In vitro, 2ME2 inhibits the proliferation of a wide variety of cell lines …

We have previously characterized the release of the signal peptide sequence-less fibroblast
growth factor (FGF) prototype, FGF-1, in vitro as a stress-induced pathway in which FGF-1 is …

FGF regulates both cell migration and proliferation by receptor-dependent induction of
immediate-early gene expression and tyrosine phosphorylation of intracellular polypeptides …

Abstract Purpose: Human papillomavirus (HPV) 16 plays an etiologic role in a growing
subset of head and neck squamous cell carcinomas (HNSCC), where viral expression of the …